NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023-Reference-Cited by-同舟云学术

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

Published:2023-11 Issue:11 Volume:21 Page:1118-1131
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Zelenetz Andrew D.¹,Gordon Leo I.²,Abramson Jeremy S.³,Advani Ranjana H.⁴,Andreadis Babis⁵,Bartlett Nancy L.⁶,Budde L. Elizabeth⁷,Caimi Paolo F.⁸,Chang Julie E.⁹,Christian Beth¹⁰,DeVos Sven¹¹,Dholaria Bhagirathbhai¹²,Fayad Luis E.¹³,Habermann Thomas M.¹⁴,Hamid Muhammad Saad¹⁵,Hernandez-Ilizaliturri Francisco¹⁶,Hu Boyu¹⁷,Kaminski Mark S.¹⁸,Karimi Yasmin¹⁸,Kelsey Christopher R.¹⁹,King Rebecca¹⁴,Krivacic Susan²⁰,LaCasce Ann S.²¹,Lim Megan¹,Messmer Marcus²²,Narkhede Mayur²³,Rabinovitch Rachel²⁴,Ramakrishnan Praveen²⁵,Reid Erin²⁶,Roberts Kenneth B.²⁷,Saeed Hayder²⁸,Smith Stephen D.²⁹,Svoboda Jakub³⁰,Swinnen Lode J.³¹,Tuscano Joseph³²,Vose Julie M.³³,Dwyer Mary A.³⁴,Sundar Hema³⁴

Affiliation:

1. Memorial Sloan Kettering Cancer Center

2. Robert H. Lurie Comprehensive Cancer Center of Northwestern University

3. Massachusetts General Hospital Cancer Center

4. Stanford Cancer Institute

5. UCSF Helen Diller Family Comprehensive Cancer Center

6. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

7. City of Hope National Medical Center

8. Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

9. University of Wisconsin Carbone Cancer Center

10. The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

11. UCLA Jonsson Comprehensive Cancer Center

12. Vanderbilt-Ingram Cancer Center

13. The University of Texas MD Anderson Cancer Center

14. Mayo Clinic Comprehensive Cancer Center

15. St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center

16. Roswell Park Comprehensive Cancer Center

17. Huntsman Cancer Institute at the University of Utah

18. University of Michigan Rogel Cancer Center

19. Duke Cancer Institute

20. Consultant

21. Dana-Farber/Brigham and Women’s Cancer Center

22. Fox Chase Cancer Center

23. O’Neal Comprehensive Cancer Center at UAB

24. University of Colorado Cancer Center

25. UT Southwestern Simmons Comprehensive Cancer Center

26. UC San Diego Moores Cancer Center

27. Yale Cancer Center/Smilow Cancer Hospital

28. Moffitt Cancer Center

29. Fred Hutchinson Cancer Center

30. Abramson Cancer Center at the University of Pennsylvania

31. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

32. UC Davis Comprehensive Cancer Center

33. Fred & Pamela Buffett Cancer Center

34. National Comprehensive Cancer Network

Abstract

Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton’s tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/21/11/article-p1118.xml

Reference86 articles.

1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms;Alaggio R,2022

2. The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee;Campo E,2022

3. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features;Navarro A,2012

4. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!;Dreyling M,2018

5. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma;Fernàndez V,2010

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Axial Field-of-View PET Imaging in Patients with Lymphoma;PET Clinics;2024-10

2. Immune Characteristics and Immunotherapy of HIV-Associated Lymphoma;Current Issues in Molecular Biology;2024-09-10

3. Bruton Tyrosine Kinase Inhibition Decreases Inflammation and Differentially Impacts Phagocytosis and Cellular Metabolism in Mouse- and Human-derived Myeloid Cells;ImmunoHorizons;2024-09-01

4. Gastrointestinal Alpha Heavy Chain Disease With Persistent Campylobacter Jejuni Colonization and Refractory Giardiasis;ACG Case Reports Journal;2024-08

5. Concurrent intestinal plasmablastic lymphoma and diffuse large B-cell lymphoma with a clonal relationship: a case report and literature review;Journal of Pathology and Translational Medicine;2024-07-15